Status:
ACTIVE_NOT_RECRUITING
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
Lead Sponsor:
Almirall, S.A.
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the tr...
Eligibility Criteria
Inclusion
- Participant with diagnosis of moderate or severe chronic plaque PSO documented in the medical chart.
- Participant who needs systemic biologic therapy and qualifies for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-Il-23p19 selected therapy before including the patient in the study.
- Participant aged greater than or equal to (\>=) 18 years at Inclusion.
- Written informed consent.
Exclusion
- Participant unable or unwilling to comply with the requirements of the study.
- Participant who should not participate in the study for any reason at the discretion of the treating physician.
- Participants participating in a simultaneous clinical trial.
- Any contraindication against the use of Tildrakizumab according to the SmPC.
- Exposure to \>= 3 biologics prior to inclusion.
- Participant dependent on the investigator, e.g. as employee
Key Trial Info
Start Date :
April 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2026
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06488170
Start Date
April 4 2024
End Date
January 1 2026
Last Update
June 24 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ostrava
Ostrava, Czechia, 708 52
2
Fakultní nemocnice Plzeň, with its registred seat at Edvarda Beneše
Pilsen, Czechia, 301 00
3
University Hospital Kralovske Vinohrady
Prague, Czechia, 100 00
4
University Hospital in Motol
Prague, Czechia, 150 06